Medical Xpress

APRIL 20, 2023

A new HIV vaccine from Scripps Research has shown a significantly improved ability to neutralize the virus in preclinical tests, and it will soon be studied in healthy people who volunteer to participate in clinical trials.

Immune Response 111

Immune Response Vaccination Vaccine Clinical Trials 111

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccination Vaccine Development 246

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

Medical Xpress

JANUARY 4, 2023

Myocarditis, a condition in which the heart muscle becomes inflamed, is a rare complication that can occur after mRNA COVID vaccination. It's estimated that roughly 18 cases occur in every 1 million vaccine doses administered, making it so rare that it is challenging to find cases to investigate.

Immune Response 91

Immune Response Protein Vaccination Vaccine 91

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.

Vaccination 52

Vaccination Vaccine Immune Response Clinical Trials 52

Pharmaceutical Technology

JUNE 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.

Vaccination 147

Vaccination Vaccine Immune Response Clinical Trials 147

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. million deaths every year.

Vaccination 81

Vaccination Vaccine Immune Response Bacteria 81

Drug Discovery World

MAY 2, 2024

A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The results suggest that previous infection, together with vaccination, offers strong protection against the original Covid-19 strain.

Vaccination 59

Vaccination Vaccine Development Immune Response 59

Scienmag

JANUARY 28, 2022

ATLANTA—An influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

Immune Response 95

Immune Response Vaccination Vaccine Research 95

Medical Xpress

MARCH 29, 2023

Researchers have found that, despite being heavily immunocompromised, hematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.

Immune Response 126

Immune Response Vaccination Vaccine Research 126

Pharmaceutical Technology

APRIL 24, 2023

Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. Langer, now a David H. Langer explains that nanoparticles can vary massively in formulation based on their uses.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

Drug Discovery World

FEBRUARY 15, 2024

The etherna paradigm for cLNP design is ushering in the rapid generation of novel families of delivery systems for not only vaccination but also for in vivo tolerisation for a host of autoimmune diseases.” The post LNP formulations produce strong immune responses, data shows appeared first on Drug Discovery World (DDW).

Immune Response 52

Immune Response In-Vivo Vaccination Vaccine 52

XTalks

FEBRUARY 19, 2024

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. Other efforts to develop a nasally-delivered COVID-19 vaccine have met with greater success.

Vaccination 110

Vaccination Vaccine Immune Response Development 110

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.

Immune Response 84

Immune Response Vaccination Vaccine Trials 84

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

The Pharma Data

OCTOBER 26, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, elicited immune responses in older coronavirus patients similar to ones generated in younger adults, lending more promise to a vaccine that’s seen as one of the leading contenders in the race to become the first approved COVID-19 vaccine. Source link.

Immune Response 52

Immune Response Vaccination Vaccine Research 52

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 104

Vaccination Vaccine Research Immune Response 104

Pharma Times

DECEMBER 8, 2023

One-third of patients who received Pfizer’s COVID-19 vaccine had unintended immune responses - News - PharmaTimes

Immune Response 126

Immune Response Research Vaccination Vaccine 126

The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Medical Xpress

DECEMBER 5, 2022

Research by RCSI University of Medicine and Health Sciences has provided new insights into the mechanism behind how our circadian 24-hour body clock influences our immune response to vaccines, depending on the time of day.

Vaccination 75

Vaccination Vaccine Immune Response Research 75

Scienmag

MARCH 10, 2022

Close interactions with infectious disease set both University of California, Santa Cruz graduate student Ana Nuñez Castrejon and Associate Professor of Biomolecular Engineering Rebecca DuBois on the path of studying Respiratory syncytial virus (RSV), a common and sometimes dangerous respiratory disease for which there is not currently a vaccine.

Immune Response 77

Immune Response Vaccination Vaccine Protein 77

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 104

Vaccination Vaccine Immune Response Allergies 104

Medical Xpress

MARCH 3, 2023

A preclinical study evaluating a Kiwi-made COVID-19 vaccine—Kiwi Vax—has shown its unique formulation induces a safe and highly effective immune response to SARS-CoV-2 variants of concern, making it a promising booster vaccine candidate.

Vaccination 105

Vaccination Vaccine Immune Response Research 105

Medical Xpress

JANUARY 25, 2023

Immunity from COVID-19 appears to gather strength with more time between vaccination and infection, a new laboratory study from researchers at Oregon Health & Science University suggests. The findings carry implications for vaccine recommendations as the pandemic transitions to an endemic state.

Immune Response 75

Immune Response Research Vaccination Vaccine 75

Drug Discovery World

APRIL 26, 2024

A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. in the combination arm and 62.2%

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

OCTOBER 22, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, currently being evaluated in phase 3 global trials, delivers a strong immune response, according to a new UK study. Source link.

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

Drug Discovery World

OCTOBER 13, 2023

The UK’s University of Oxford is taking the lead on two collaborative international projects to improve the response to new Covid-19 variants and contribute to future pandemic preparedness. The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses.

Vaccination 105

Vaccination Vaccine Immune Response Scientist 105

Pharma Times

JUNE 29, 2021

Mixing different vaccines produces a strong immune response against virus, according to researchers

Immune Response 125

Immune Response Vaccination Vaccine Research 125

BioSpace

NOVEMBER 7, 2022

Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.

Immune Response 95

Immune Response Vaccination Vaccine Protein 95